<DOC>
	<DOCNO>NCT02184156</DOCNO>
	<brief_summary>In Phase I/Phase II clinical trial , 7 eligible patient OA knee receive Ampion™ 4 mL administer three IA injection , 2 week apart . In absence serious drug-related AEs unanticipated drug-related AEs , enrollment initiate Phase II study . In Phase II , total 30 eligible patient OA knee pain randomize 1:1 receive either active drug ( Ampion™ 4 mL ) placebo three IA injection , 2 week apart .</brief_summary>
	<brief_title>AP-007 Study Evaluate Safety Exploratory Efficacy Three Intra-articular Injections Ampion Knee Adults With Pain Due Osteoarthritis</brief_title>
	<detailed_description>In Phase I study , 7 eligible patient OA knee pain enrol treat 3 IA injection active drug ( Ampion™ 4 mL ) Baseline ( Day 0 ) Weeks 2 4 knee . The Medical Monitor conduct safety evaluation 7 treated patient complete Week 4 follow-up evaluation . Enrollment initiate Phase II serious drug-related adverse event unanticipated drug-related adverse event observe . Pending safety review , patient continue Week 52 . In Phase II , 30 eligible patient OA knee pain enrol randomize , placebo-controlled , double-blind phase study . Patients randomize 1:1 receive three ( 3 ) IA injection either active drug ( Ampion™ 4 mL ) placebo Baseline ( Day 0 ) Weeks 2 4 knee . The clinical effect treatment OA pain evaluate patient in-clinic visit Screening , Baseline ( Day 0 ) Weeks 2 , 4 , 6 , 12 , 18 , 20 , 24 52 use Western Ontario McMaster Universities Arthritis Index ( WOMAC® ) osteoarthritis Index 3.1 , Patient 's Global Assessment disease severity ( PGA ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Clinical diagnosis radiological evidence symptomatic osteoarthritis knee Moderate severe pain Other condition knee , e.g. , crystal arthropathy , septic necrosis , joint replacement , major injury within 12 month prior screen , tense effusion Requires ongoing treatment intraarticular pain medication systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>